7th SYMPOSIUM ON THE NEUROVIROLOGY
AND NEUROIMMUNOLOGY OF SCHIZOPHRENIA AND BIPOLAR DISORDER
FOCUS ON GENOMICS, PROTEOMICS, AND
CLINICAL TRIALS
AGENDA
Genomics and Proteomics
TO THE STANLEY BRAIN COLLECTION
E. Fuller Torrey and Maree Webster, Stanley Medical Research Institute
OF RNA THAT AFFECT cDNA GENERATION AND ARRAY HYBRIDIZATION
Christine L. Miller and Robert H. Yolken, Stanley Division of Developmental
Neurovirology, Johns Hopkins University
ANALYSES OF GENOMIC AND PROTEOMIC MEASUREMENTS IN HUMAN POSTMORTEM BRAIN TISSUE
Dawn Dhavale, Stanley Medical Research Institute
Genomic Studies of Schizophrenia and
Bipolar Disorder
EXPRESSION ANALYSIS IN SCHIZOPHRENIA: REPRODUCIBLE UPREGULATION OF SEVERAL
MEMBERS OF THE APOLIPOPROTEIN L FAMILY LOCATED IN A HIGH SUSCEPTIBILITY LOCUS
FOR SCHIZOPHRENIA ON CHROMOSOME 22
Sabine Bahn, Addenbrook’s Hospital, University of Cambridge
ANALYSIS OF THE STANLEY BRAIN COLLECTION
Pamela Sklar, Whitehead Institute
EXPRESSION IN SCHIZOPHRENIA BY cDNA MICROARRAY
Marquis P. Vawter, University of California at Irvine
DISEASE OF THE SYNAPSE
Karoly Mirnics, University of Pittsburgh
Genomic Studies of Other
Neuropsychiatric Diseases
RNA PROFILING IN NEUROPSYCHIATRIC AND NEURODEGENERATIVE
DISORDERS
Allen Fienberg, Rockefeller University
AND STRATEGIES FOR STUDYING GENE EXPRESSION CHANGES IN PSYCHIATRIC DISEASE
C. Anthony Altar, Psychiatric Genomics, Inc., Gaithersburg, MD
OF A NEUROPSYCHIATRIC cDNA ARRAY
Kevin Becker, DNA Array Unit, NIA, NIH, Baltimore, MD
THE BRAIN WITH MICROARRAYS – DATA ANALYSIS ISSUES
Simon Lin, Bioinformatics, Duke University
EXPRESSION CHANGES FOLLOWING NEONATAL VENTRAL HIPPOCAMPAL LESIONS
Graham K. Wood, McGill University, Montreal PQ, Canada
Proteomic Studies of Schizophrenia
HUMAN BRAIN PROTEOME: INITIAL RESULTS FROM THE HUMAN PROTEIN INDEX™ PROJECT
Leigh Anderson, Large Scale Biology Corporation
PROTEOMICS FOR PROFILING OF NEUROPSYCHIATRIC DISEASE
Eric Fung, Ciphergen Biosystems, Fremont, CA
Poster Presentations
EXAMINATION OF REGIONAL DISTRIBUTION OF HUMAN CORONAVIRUS RNA IN POST MORTEM
HUMAN BRAIN
Arlene R. Collins, Lynn Diviak, Alicia Arnold and Mary J. Evans, State
University of New York at Buffalo
CLONALLY EXPANDED T CELLS ARE PRESENT
IN THE CSF OF PATIENTS WITH MAJOR DEPRESSION
Emilia Oleszak, Temple University School of
Medicine, Philadelphia, PA
STUDIES – AN INTEGRATIVE PLATFORM FOR CASE-CONTROL STUDIES AND ANIMAL MODELS OF
SCHIZOPHRENIA
Francois Feron, Queensland Centre for
Schizophrenia Research, Australia
LEVELS OF REELIN AND ITS ISOFORMS IN SCHIZOPHRENIA AND MOOD DISORDERS
SH Fatemi, University of Minnesota
EXPRESSION IN SUBJECTS WITH MOOD DISORDERS AND LITHIUM-TREATED RATS
Yarema B. Bezchlibnyk, Jun-Fen Wang, Glenda M. MacQueen, L. Trevor Young,
McMasters University
OF BROADLY AMPLIFYING REAL TIME PCRs FOR DETECTION AND QUANTIFICATION OF
RETROVIRAL NUCLEIC ACID
Jonas Blomberg, Uppsala, Sweden
DNA STABILITY AND SCHIZOPHRENIA IN TWINS
Cassandra L. Smith, Boston University
RETROVIRAL REACTIVITY OF PERINATAL SERA
FROM MOTHERS WHOSE CHILDREN DEVELOPED SCHIZOPHRENIA
Erik P. Lillehoj, Steve Buka, E. Fuller Torrey, Robert H. Yolken
EVALUATION OF VIRUSES AND INTRACELLULAR BACTERIA STATUS IN URBAN CATS AND THEIR
RELATIONSHIP WITH DEVELOPMENT OF SCHIZOPHRENIA IN HUMAN
Reza Firouzi, Lyons, France
ASSESSMENT OF RETROVIRAL ACTIVITY IN HUMAN BRAIN AND TISSUE
Wolfgang Seifarth, University of Heidelberg, Germany
PROTEIN BY WESTERN IMMUNOBLOT IN SAMPLES REACTIVE TO BARTONELLA HENSELAE
BY AN IMMUNOFLUORESCENT ASSAY
Glen Ford, Roveko, Gaithersburg, MD
IN UTERO EXPOSURE TO INFLUENZA A
VIRUS, TRANSPLACENTAL PASSAGE AND INFLUENCE ON GENE EXPRESSION IN THE FETAL
MOUSE BRAIN
Håkan, Karlsson, Karolinska Institute
DEFICIENT CALCIUM-DEPENDENT NITRIC OXIDE SYNTHASE ACTIVITY IN
THE PREFRONTAL CORTEX OF SCHIZOPHRENIA AND DEPRESSION
Guoqiang Xing, USUHS, Bethesda, Md
Clinical Trials
MODELS OF DRUG DEVELOPMENT FOR THE TREATMENT OF SCHIZOPHRENIA
Jeffrey A. Lieberman, University of North Carolina School of Medicine
EXPRESSION ANALYSIS REVEALS DYSREGULATION OF MYELINATION-RELATED GENES IN
CHRONIC SCHIZOPHRENIA
Kenneth L. Davis, Mt. Sinai School of Medicine
MEDICATION STRATEGIES FOR RELAPSE PREVENTION IN SCHIZOPHRENIA
John Kane, Hillside Hospital
FUTURE PSYCHOPHARMACOLOGY OF MOOD AND ANXIETY DISORDER
Dennis S. Charney, NIH
OF NEUROTROPHIC SIGNALING CASCADES BY MOOD STABILIZING AGENTS: PUTATIVE
MEDIATORS OF LONG TERM THERAPEUTIC EFFECTS IN BIPOLAR DISORDER
Husseini K. Manji, National Institute of Mental Health
VIVO BRAIN IMAGING AND DRUG DEVELOPMENT
Clinton Kilts, Emory University School of Medicine, Atlanta, GA
AGENTS FOR SCHIZOPHRENIA
Norbert Müller, Ludwig-Maximilians University
STRATEGIES FOR NEW DRUG DEVELOPMENT
Anil K. Malhotra, Hillside Hospital, Albert Einstein College of Medicine
POTENTIAL ROLE IN HUMAN PSYCHIATRIC DISEASES
Robert H. Yolken, Stanley Division of Developmental Neurovirology, Johns
Hopkins University
SELECTING TARGETS FOR DRUG DEVELOPMENT IN SCHIZOPHRENIA
Carol A. Tamminga, University of Maryland School of Medicine
PSYCHOSIS
John M. Davis, University of Illinois at Chicago
PROCESSES MAINTAINING FUNCTION AFTER GENE DELETION OF DA RECEPTOR SUBTYPES
INDICATE NOVEL DRUG TARGETS
John L. Waddington, Royal College of Surgeons in Ireland